Inventor
WALTER KORDEN
DE18 patents
⚠️ This page may combine multiple inventors who share the name “WALTER KORDEN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
GANYMED PHARMACEUTICALS AG
7 patentsUS10233253B2Mar 19, 2019
Antibodies for treatment of cancer expressing claudin 6
GANYMED PHARMACEUTICALS AG7 citations83
US10919974B2Feb 16, 2021
Antibodies for treatment of cancer expressing claudin 6
GANYMED PHARMACEUTICALS AG0 citations61
US9932401B2Apr 3, 2018
Antibodies specific for claudin 6 (CLDN6)
GANYMED PHARMACEUTICALS AG1 citations61
US9902778B2Feb 27, 2018
Cancer therapy using CLDN6 target-directed antibodies in vivo
GANYMED PHARMACEUTICALS AG1 citations61
US11473085B2Oct 18, 2022
Methods and compositions for diagnosis and treatment of cancer
GANYMED PHARMACEUTICALS AG1 citations57
US10844133B2Nov 24, 2020
Cancer therapy using CLDN6 target-directed antibodies in vivo
GANYMED PHARMACEUTICALS AG0 citations51
US10745477B2Aug 18, 2020
Antibodies specific for claudin 6 (CLDN6)
GANYMED PHARMACEUTICALS AG0 citations51
SAHIN UGUR
4 patentsUS9487584B2Nov 8, 2016
Antibodies specific for claudin 6 (CLDN6)
SAHIN UGUR19 citations92
US9718886B2Aug 1, 2017
Cancer therapy using CLDN6 target-directed antibodies in vivo
SAHIN UGUR13 citations91
US9321842B2Apr 26, 2016
Antibodies for treatment of cancer
SAHIN UGUR14 citations91
US9809815B2Nov 7, 2017
Methods and compositions for diagnosis and treatment of cancer
SAHIN UGUR0 citations49
GANYMED PHARMACEUTICALS GMBH
3 patentsUS11859008B2Jan 2, 2024
Antibodies for treatment of cancer expressing claudin 6
GANYMED PHARMACEUTICALS GMBH2 citations71
US11541127B2Jan 3, 2023
Drug conjugates comprising antibodies against claudin 18.2
GANYMED PHARMACEUTICALS GMBH2 citations71
US11858988B2Jan 2, 2024
Antibodies specific for claudin 6 (CLDN6)
GANYMED PHARMACEUTICALS GMBH0 citations61